Media coverage about Fresenius Medical Care AG & Co. (NYSE:FMS) has been trending somewhat positive on Wednesday, Accern reports. Accern rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Fresenius Medical Care AG & Co. earned a news impact score of 0.16 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.801564594832 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

FMS has been the topic of a number of research reports. Royal Bank of Canada reiterated a “hold” rating and set a $44.00 target price on shares of Fresenius Medical Care AG & Co. in a report on Wednesday, September 13th. Zacks Investment Research lowered shares of Fresenius Medical Care AG & Co. from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. DZ Bank reiterated a “buy” rating on shares of Fresenius Medical Care AG & Co. in a report on Monday, November 13th. Morgan Stanley lowered shares of Fresenius Medical Care AG & Co. from an “overweight” rating to an “equal weight” rating in a report on Monday, December 11th. Finally, SunTrust Banks set a $62.00 target price on shares of Fresenius Medical Care AG & Co. and gave the stock a “buy” rating in a report on Thursday, December 21st. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $55.67.

Shares of Fresenius Medical Care AG & Co. (NYSE:FMS) traded down $0.94 during trading hours on Wednesday, hitting $54.27. 191,238 shares of the company’s stock were exchanged, compared to its average volume of 158,386. Fresenius Medical Care AG & Co. has a 52 week low of $39.85 and a 52 week high of $55.30. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.98 and a current ratio of 1.22. The stock has a market cap of $33,340.00, a P/E ratio of 22.33, a PEG ratio of 2.26 and a beta of 0.45.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-fresenius-medical-care-ag-co-fms-share-price/1801846.html.

Fresenius Medical Care AG & Co. Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Insider Buying and Selling by Quarter for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.